Denali Therapeutics Inc
$ 21.02
1.99%
11 Jun - close price
- Market Cap 3,336,079,000 USD
- Current Price $ 21.02
- High / Low $ 21.68 / 20.37
- Stock P/E N/A
- Book Value 5.84
- EPS -2.88
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.50 %
- 52 Week High 23.77
- 52 Week Low 12.58
About
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$33.93
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-27 | 2024-11-06 | 2024-08-01 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 | -0.67 | -0.63 | -0.59 | -0.78 | -0.86 | -0.72 | 1.3 |
| Estimated EPS | -0.71 | -0.75 | -0.76 | -0.74 | -0.7 | -0.8459 | -0.63 | -0.69 | -0.66 | -0.8 | -0.79 | -0.63 |
| Surprise | 0.02 | 0.02 | 0.02 | 0.02 | -0.08 | 0.1759 | 0 | 0.1 | -0.12 | -0.06 | 0.07 | 1.93 |
| Surprise Percentage | 2.8169% | 2.6667% | 2.6316% | 2.7027% | -11.4286% | 20.7944% | 0% | 14.4928% | -18.1818% | -7.5% | 8.8608% | 306.3492% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.6 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNLI
2026-06-11 09:09:48
This article discusses Denali Therapeutics Inc. (NASDAQ: DNLI) as one of the top AI-driven biotech stocks. It details the company's recent Phase 2b LUMA trial results for Parkinson's disease, which missed primary endpoints but showed biological target engagement. Despite a lowered price target from Morgan Stanley, Denali plans further trials for a specific genetic mutation, and the firm still sees significant upside potential.
2026-06-11 05:20:00
Denali Therapeutics (DNLI) is highlighted as a top AI-driven biotech stock despite a recent setback. The company's joint work with Biogen on BIIB122 for Parkinson's disease was halted after Phase 2b trial results showed no improvement over placebo. However, lab tests confirmed the drug hit its biological targets, and Denali plans to continue independent trials for a specific genetic mutation, with Morgan Stanley maintaining an "Overweight" rating and a price target suggesting significant upside.
2026-06-10 22:36:00
The failure of Biogen and Denali’s LRRK2 inhibitor (BIIB122) in a Phase IIb study for Parkinson's disease, which enrolled patients regardless of LRRK2 genetic variant status, is redirecting research focus. This setback suggests that future trials for LRRK2 inhibitors may need to prioritize genetically enriched patient populations, rather than broadly targeting all Parkinson's patients. Denali is now independently testing BIIB122 in a smaller trial specifically limited to confirmed variant carriers.
2026-06-06 01:39:18
Denali Therapeutics (DNLI) director Timothy Van Hauwermeiren received new equity awards comprising 6,408 Restricted Stock Units (RSUs) and options to purchase 19,226 shares. These awards are part of his compensation, not open-market transactions, and will vest 100% on the earlier of one year from the grant date or the day before Denali's next annual meeting. Following these grants, he holds 17,040 unvested RSUs.
2026-06-05 21:09:31
Denali Therapeutics director Nancy Thornberry was granted 6,408 Restricted Stock Units (RSUs) and a stock option for 19,226 shares with an exercise price of $19.66. Both equity awards will vest upon the earlier of one year from the grant date or the day before the next annual stockholder meeting. Following these transactions, Thornberry directly holds 31,125 shares of common stock, including the unvested RSUs.
2026-06-05 20:09:30
Denali Therapeutics (NASDAQ: DNLI) director Julian C. Baker was granted 6,408 restricted stock units (RSUs) and 19,226 non-qualified stock options, with a strike price of $19.66, vesting in 2027. These equity awards are compensation for his board service and are indirectly held by Baker Brothers funds. The transaction is considered routine compensation, not open-market trading, and significantly increases the Baker complex's potential future exposure to Denali.
